CAS: 56161-70-7; N-Methyl-3-Phenoxy-3-Phenylpropan-1-Amine

上下游产品

3-methylamino-1-phenylpropan-1-ol N-methyl-3-chloro-3-phenylpropylamine phenol 3-iodo-1-phenyl-propan-1-ol9,10-dihydro-N-methyl-9-oxo-N-(3-phenoxy-3-phenylpropyl)acridine-4-carboxamide

📜1-氯-3-苯基丙烷置于n-溴代丁二酰亚胺(Nbs),四丁基碘化铵,Sodium Hydride,Potassium Carbonate,过氧化苯甲酰体系中,用 甲醇,N,N-二甲基甲酰胺,氯苯,Mineral Oil 作为反应溶剂,化学反应 40.5H,反应生成 阿托西汀ep杂质a
参考文献:Molecular Basis For Selective Serotonin Reuptake Inhibition By The Antidepressant Agent Fluoxetine (Prozac)
标题:Molecular Basis For Selective Serotonin Reuptake Inhibition By The Antidepressant Agent Fluoxetine (Prozac)
摘要:血清素转运体(sert)的抑制剂被广泛用作抗抑郁剂,但其抑制活性和对密切相关的去甲肾上腺素转运体(net)的选择性背后的结构机制尚不清楚.在这里,我们结合化学,生物学和计算方法,解析了典型抗抑郁药物氟西汀(prozac;礼来制药,印第安纳波利斯)在sert中的高亲和力识别以及对net的选择性的分子基础.我们发现氟西汀结合在人体sert的中心底物位点,这与最近的leubat X射线晶体结构保持一致,Leubat是细菌氨基酸转运蛋白leut的工程化单胺样版本.然而,在我们支持的实验模型中,氟西汀的结合方向与leubat结构相比是反向的,这强调了在将细菌转运体的晶体结构发现推及到与人类相关的转运体时需要进行谨慎的实验验证.我们发现氟西汀和其net选择性结构同源物nisoxetine的选择性由转运体不同区域的氨基酸残基控制,这表明在sert和net中对结构相似化合物具有复杂的选择性识别机制.我们的发现为抗抑郁剂的sert/net选择性的分子基础提供了重要的新信息,并首次评估了leubat作为人类转运体中抗抑郁药结合模型系统的潜力,这对于未来基于结构的抗抑郁药物开发具有重要意义,特别是对转运体选择性的细致调控.
DOI:10.1124/mol.113.091249

专利信息

专利号:US-2008004470-A1
优先权日:2004-09-27
标 题:Synthesis of Atomoxetine Hydrochloride
发明人：MATHAD VIJAYAVITTHAL T; GHANTA MAHESH R; GOVINDAN SHANMUGAM; MACHARLA PRABHAKAR; NALIVELA VENU
权利人:MATHAD VIJAYAVITTHAL T; GHANTA MAHESH R; GOVINDAN SHANMUGAM; MACHARLA PRABHAKAR; NALIVELA VENU
摘要:(±)-Atomoxetine oxalate having crystalline Form II and a solid (±)-atomoxetine free base are useful in preparing atomoxetine hydrochloride.

专利号:WO-2008062473-A1
优先权日:2006-10-31
标 题 :Process for preparing atomoxetine hydrochloride
发明人：PATEL VIPUL KANTIBHAI; KUMAR RAJIV; DHAR DWIVEDI SHRIPRAKASH
权利人:CADILA HEALTHCARE LTD; PATEL VIPUL KANTIBHAI; KUMAR RAJIV; DHAR DWIVEDI SHRIPRAKASH
摘要:The present invention relates to the process for preparing Atomoxetine hydrochloride which is a selective norepinephrine reuptake inhibitor. Atomoxetine HCl is chemically known as (-)-iV-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride and represented by formula (I). More particularly, the invention relates to crystalline form of N-methyl-3-phenyl-3-(o- tolyloxy) propylamine oxalate (here in after referred as '(±) Atomoxetine Oxalate'), which is an useful intermediate for the synthesis of Atomoxetine hydrochloride.

专利号:US-6458955-B1
优先权日:1994-12-16
标 题 :Process for preparation of pharmaceutically desired enantiomers
发明人：GATTUSO MARK J
权利人:UOP LLC
摘要:Improved processes for preparation of high enantiomeric purity compounds center on resolution using simulated moving bed chromatography of a racemic precursor early in the synthesis. Resolution is effected with high enantiomeric purity, and subsequent reactions of the desired enantiomer performed with high optical specificity to maintain enantiomeric purity. The undesired enantiomer is racemized and recycled to the resolution phase to avoid loss.

专利号:WO-2006037055-A1
优先权日:2004-09-27
标题 :Synthesis of atomoxetine hydrochloride